Currency In USD
| Previous Close | 3.18 |
| Open | 3.1 |
| Day High | 3.42 |
| Day Low | 2.94 |
| 52-Week High | 14.64 |
| 52-Week Low | 2.94 |
| Volume | 51,718 |
| Average Volume | 64,332 |
| Market Cap | 9.42M |
| PE | -0.55 |
| EPS | -5.59 |
| Moving Average 50 Days | 4.95 |
| Moving Average 200 Days | 8.41 |
| Change | -0.12 |
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therape
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
GlobeNewswire Inc.
Feb 24, 2026 1:30 PM GMT
Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 Meeting Scheduled for March 2026 PONTE VEDRA, Fla
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Company to also participate in Fireside Chat at Lytham Partners 2026 Investor Healthcare Summit on Thursday, January 15, 2026SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company de